Accelerated Approval: Sponsor Size No Excuse For Confirmatory Trial Delays, FDA Says

There is a greater commitment among larger, well-capitalized oncology companies to complete confirmatory trials, Oncology Center of Excellence Director Richard Pazdur says; smaller company approach of first getting accelerated approval and then using commercial proceeds to capitalize confirmatory trial is ‘unacceptable.’

Spheres
Big or small, the size of a company doesn't matter when it comes to the obligation for timely conduct of confirmatory studies. • Source: Shutterstock

More from US FDA Performance Tracker

More from Regulatory Trackers